Clinical Trial

Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

Name: Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors — clinical trial record (NCT07275853)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

Trial Details

NCT Number	NCT07275853
Lead Sponsor	TCRx Therapeutics Co.Ltd Collaborators: Chinese Academy of Medical Sciences
Conditions	Advanced Solid Tumors
Enrollment	30 participants
Start Date	2025-12-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-10